Merck's Keytruda boosts response in hard-to-treat lung cancer


The combination of Merck & Co's immunotherapy Keytruda and chemotherapy boosted response rates in patients with advanced hard-to-treat squamous cell lung cancer, the company said on Wednesday. FILE PHOTO: The logo of Merck is pictured in this illustration photograph in Cardiff, California, U.S., April 26, 2016.



from Biotech News